FemSoft Consumer, Physician Ad Campaign Planned By Rochester Medical
This article was originally published in The Gray Sheet
Rochester Medical's marketing strategy for the FemSoft insert for treatment of female stress urinary incontinence will include campaigns aimed at both physicians and consumers.
You may also be interested in...
FDA approval of Rochester Medical's FemSoft insert for female stress urinary incontinence on Sept. 30, the final day of the federal government's fiscal year, apparently put the agency's total number of approved, original premarket approval applications for the year at 33, down from 42 in 1998 and 46 in 1997.
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.